Xcout Intel
Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Subscribe to see Septerna, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Septerna, Inc. at a glance
Septerna, Inc. is a biotechnology company headquartered in South San Francisco, United States. It is publicly listed (SEPN) with a market capitalisation of $1.7B. Xcout tracks 30 named people at Septerna, Inc., including Elizabeth Bhatt (President & Chief Operating Officer). Xcout recorded 9 job postings from Septerna, Inc. in the last 90 days.
Septerna, Inc. leadership
- Elizabeth BhattPresident & Chief Operating Officer
- Liz Bhatt, MS, MBAPresident and Chief Operating Officer
- Gilbert LabrucherieChief Financial Officer
- Gil Labrucherie, CFA, JDChief Financial Officer
- Samira ShaikhlyChief People Officer
- Mark A WilsonChief Legal Officer
24 more named people on record for Septerna, Inc., with roles, board committees and tenure — see the full roster →
Septerna, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $150M | 3 named | |
| — | $100M | 4 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Septerna, Inc.
Xcout recorded 9 job postings from Septerna, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Septerna, Inc.'s hiring signals →
Investors
Septerna, Inc. competitors
A few of Septerna, Inc.'s closest competitors — see the full list of competitors and alternatives →
Domain Therapeutics is a French biopharmaceutical company focused on discovering and developing drugs that target G-protein-coupled receptors (GPCRs), including applications in oncology and immuno-oncology. It serves pharmaceutical and biotechnology partners through proprietary drug-discovery programs, technology platforms, and licensing or collaboration agreements.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
RayThera is a small molecule drug discovery company founded in August 2023, headquartered in San Diego, CA, United States. Its mission is to develop safer, more effective therapeutics by advancing drug discovery with proven expertise and adaptable approaches. The company focuses on transformative therapies for unmet medical needs.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company headquartered at the Pacific Research Center in Newark, California, focused on peptide drug discovery.
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.
Get Septerna, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Septerna, Inc. in Xcout Intel
- 30 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access